EOS789

EOS789 is a first-in-class, orally administered small molecule that acts as a pan-phosphate transporter inhibitor. It noncompetitively inhibits multiple sodium-dependent phosphate transporters—specifically NaPi-IIb (SLC34A2), PiT-1 (SLC20A1), and PiT-2 (SLC20A2)—with reported IC50 values of 6.8 μM for NaPi-IIb, 1.5 μM for PiT-1, and 1.7 μM for PiT-2[5][3][7]. By blocking these transporters in the intestine and kidney, EOS789 reduces intestinal phosphate absorption and lowers serum phosphate levels. This mechanism is particularly relevant in the management of hyperphosphatemia associated with chronic kidney disease-mineral bone disorder (CKD-MBD)[4][2]. Preclinical studies have shown that EOS789 also decreases serum FGF23 and parathyroid hormone levels in animal models[5], ameliorates tubulointerstitial fibrosis and glomerular sclerosis in rodent CKD models[8], and may reduce sodium absorption due to its action on sodium-driven transporters[8]. The drug was discovered by Chugai Pharmaceutical and is being co-developed with Shanghai Alebund Pharmaceuticals[3][7].

Other names

AP306AP-306AP 306EOS 789EOS789EOS-789